Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved participants across eight groups (called cohorts or arms), who were tested at different stages — a Treatment Period 1, a Treatment Period 2, and an Extension phase. In Treatment Period 1, 16 people started and 10 completed that phase. In Treatment Period 2, a total of 60 people started across six groups, with varying numbers completing. In the Extension phase, 28 people started and 21 completed. The trial was measuring the safety profile of the study drug (AIN457, also known as secukinumab) in people with uveitis (inflammation inside the eye), as well as looking at how many participants showed a meaningful improvement in their eye condition. The reported data shows that for the primary outcome — counting the number of participants who experienced unwanted health events (called adverse events), serious unwanted health events, or death — small numbers were recorded across the groups: one participant each in Cohort 3, Cohort 5, and Cohort 2 experienced adverse events, while no deaths were reported in the data provided. For the secondary outcomes, the reported data shows that a small number of participants across certain groups met the definition of a "responder" (meaning they showed at least one meaningful improvement in vision, eye inflammation, or were able to reduce their steroid medication) at Day 57: for example, one responder each was reported in Cohorts 2, 6 Arm 1, and 6 Arm 2, and three in Cohort 6 Arm 3. Similarly, small numbers of "complete responders" (those who were able to stop all steroid medications and maintain improvement) were reported across some groups. The reported data also notes that several other planned secondary outcomes — including measuring reductions in steroid use and rates of remission — were not formally analysed and no summary numbers were provided. According to the results reported on ClinicalTrials.gov, this was because the overall number of participants was too small and initial drug doses were too low to draw meaningful conclusions about how the dose related to outcomes. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 25638011) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have active uveitis (an inflammatory eye condition that is currently flaring up, not in remission).
- Your uveitis affects the middle, back, or the whole of the eye, and is severe enough that your doctor has determined you need medication that affects your whole immune system.
Who may not be able to join:
- You currently have an active infection of any kind.
- You weigh more than 120 kilograms (approximately 265 pounds).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.